4.5 Article

Germline TP53 Variants and Susceptibility to Osteosarcoma

期刊

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djv101

关键词

-

类别

资金

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health
  2. Children's Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD [U10 CA180886-01, U24 CA114766]
  3. WWWW (QuadW) Foundation, Inc.
  4. Ontario Cancer Research Network
  5. Canadian Institutes of Health Research
  6. Ontario Research Fund
  7. Canadian Foundation for Innovation

向作者/读者索取更多资源

The etiologic contribution of germline genetic variation to sporadic osteosarcoma is not well understood. Osteosarcoma is a sentinel cancer of Li-Fraumeni syndrome (LFS), in which approximately 70% of families meeting the classic criteria have germline TP53 mutations. We sequenced TP53 exons in 765 osteosarcoma cases. Data were analyzed with chi(2) tests, logistic regression, and Cox proportional hazards regression models. We observed a high frequency of young osteosarcoma cases (age <30 years) carrying a known LFS- or likely LFS-associated mutation (3.8%) or rare exonic variant (5.7%) with an overall frequency of 9.5%, compared with none in case patients age 30 years and older (P < .001). This high TP53 mutation prevalence in young osteosarcoma cases is statistically significantly greater than the previously reported prevalence of 3% (P = .0024). We identified a novel association between a TP53 rare variant and metastasis at diagnosis of osteosarcoma (rs1800372, odds ratio = 4.27, 95% confidence interval = 1.2 to 15.5, P = .026). Genetic susceptibility to young onset osteosarcoma is distinct from older adult onset osteosarcoma, with a high frequency of LFS-associated and rare exonic TP53 variants.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据